

Claims

1. A planiplaniform transmucosal pharmaceutical administration form which is distinguished by low solubility within the oral cavity and release of active compound which is rapid and constant over a relatively long period, characterized in that it is composed of a solid solution of the active compound
- 5 a) in a phosphatidylcholine fraction in which the fatty acid residues are at least 90% saturated, or
- b) in a mixture of the phosphatidylcholine fraction specified under a) and a copolymer composed of maleic acid and an alkyl vinyl ether,
- 10 and, where appropriate, further pharmaceutically tolerated adjuvants and additives.
2. The administration form as claimed in claim 1, characterized in that it comprises at least 80% by weight of the phosphatidylcholine fraction in accordance with a).
- 15 3. The administration form as claimed in claim 1 or 2, characterized in that it comprises polyvinylpyrrolidone as additive.
- 20 4. The administration form as claimed in one of claims 1 to 3, characterized in that the active compound is suitable for treating the abuse of addiction-inducing drugs and dependence on these drugs.
5. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is a fused indole derivative and/or its acid addition salt.
- 25 6. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is 7-azabicyclo(2.2.1)heptane, 7-azabicyclo(2.2.1)heptene and/or a derivative of this compound.
- 30

7. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is ebibatidine and/or a derivative of this compound.

5 8. The administration form as claimed in one or more of claims 1 to 4, characterized in that the active compound is a benzylidene- and cinnamylidene-annabasiene or a derivative of this compound.

9. The administration form as claimed in one or more of claims 1 to 4,
10 characterized in that the active compound is selected from the compound group mecamylamine, hypericin, CP-52655 and bupropion and/or one of their derivatives.

10. The administration form as claimed in one or more of claims 1 to 4,
15 characterized in that the active compound is selected from the group of oxazolidinone derivatives and befloxacines.

11. The administration form as claimed in one or more of claims 1 to 4,
characterized in that the active compound is the cannabinoid receptor (CB 1)
20 antagonist SR 141716.